Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

279 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD155 as an emerging target in tumor immunotherapy.
Wu JW, Liu Y, Dai XJ, Liu HM, Zheng YC, Liu HM. Wu JW, et al. Among authors: zheng yc. Int Immunopharmacol. 2024 Apr 20;131:111896. doi: 10.1016/j.intimp.2024.111896. Epub 2024 Mar 22. Int Immunopharmacol. 2024. PMID: 38518596 Review.
[UGT1A1 gene mutation spectrum with indirect hyperbilirubinemia in children].
Shen Y, Guo HM, Zheng YC, Zheng BX, Yan KL, Kong GP, Lin Q, Jin Y, Liu ZF, Li M. Shen Y, et al. Among authors: zheng yc. Zhonghua Gan Zang Bing Za Zhi. 2024 Feb 20;32(2):119-124. doi: 10.3760/cma.j.cn501113-20230115-00030.. Zhonghua Gan Zang Bing Za Zhi. 2024. PMID: 38514260 Chinese.
Degraders in epigenetic therapy: PROTACs and beyond.
Dai XJ, Ji SK, Fu MJ, Liu GZ, Liu HM, Wang SP, Shen L, Wang N, Herdewijn P, Zheng YC, Wang SQ, Chen XB. Dai XJ, et al. Among authors: zheng yc. Theranostics. 2024 Jan 27;14(4):1464-1499. doi: 10.7150/thno.92526. eCollection 2024. Theranostics. 2024. PMID: 38389844 Free PMC article. Review.
USP7 as an emerging therapeutic target: A key regulator of protein homeostasis.
Guo NJ, Wang B, Zhang Y, Kang HQ, Nie HQ, Feng MK, Zhang XY, Zhao LJ, Wang N, Liu HM, Zheng YC, Li W, Gao Y. Guo NJ, et al. Among authors: zheng yc. Int J Biol Macromol. 2024 Apr;263(Pt 1):130309. doi: 10.1016/j.ijbiomac.2024.130309. Epub 2024 Feb 19. Int J Biol Macromol. 2024. PMID: 38382779 Review.
Corrigendum to "Re: Pathologic complete responses, long-term outcomes, and recurrence patterns in HER2-low vs. HER2-zero breast cancer after neoadjuvant chemotherapy: Several issues about HER2 expression and neoadjuvant chemotherapy in breast cancer" [Eur J Cancer 180 (2023) 184-185].
Yang F, Liu G, Mao F, Zheng YC. Yang F, et al. Among authors: zheng yc. Eur J Cancer. 2024 Mar;200:113559. doi: 10.1016/j.ejca.2024.113559. Epub 2024 Feb 2. Eur J Cancer. 2024. PMID: 38310078 No abstract available.
279 results